Evidence & concentration worksheet · Brain Health & Nootropics
PE-22-28 10 mg
Human efficacy and a validated dose have not been established for this compound. The former regimen has been withheld; only concentration arithmetic remains available.
Evidence review
No established human dosing protocol
Human efficacy and a validated dose have not been established for this compound. The former regimen has been withheld; only concentration arithmetic remains available.
How it works
PE-22-28 is a seven-amino-acid shortened analogue of spadin designed to inhibit the TREK-1 potassium channel. It is an experimental neuroscience compound with no FDA-approved product, psychiatric indication, or human dose.
Benefits & side effects
Cell experiments found potent TREK-1 inhibition, and mouse behavioral tests reported antidepressant-like effects, neurogenesis markers, and synaptogenesis-related changes.[1] Forced-swim and novelty-suppressed-feeding results are screening signals, not diagnoses or clinical outcomes. Teloryx found no controlled human efficacy, pharmacokinetic, or safety trial.
Calculator
Concentration and measurement calculator
Use this only to check arithmetic from an authoritative product label, registered study protocol, or qualified clinician.
Arithmetic only — not a dose recommendation
Enter only a concentration and target supplied by an authoritative product label, a registered study protocol, or a qualified clinician. A correct conversion does not establish that a substance, vial, route, or dose is safe or effective.
Enter only a concentration and target supplied by an authoritative product label, a registered study protocol, or a qualified clinician. A correct conversion does not establish that a substance, vial, route, or dose is safe or effective.
Source concentration
Source-supplied target
References
References
- Frontiers in Pharmacology — Shortened spadin analogs: TREK-1 inhibition and mouse behavioral models (2017)
- U.S. FDA — Understanding the risks of compounded drugs (2026)